Most Read Articles
Audrey Abella, 14 Oct 2019
Use of the Zephyr endobronchial valve (EBV) led to significant improvements in a range of patient-reported outcomes (PROs) including multiple domains of respiratory symptoms and quality of life (QoL) in patients with severe emphysema, according to the post hoc results of the LIBERATE* trial presented at ERS 2019.
14 Oct 2019
Dr Helene Kobbernagel expounds on the role of azithromycin in primary ciliary dyskinesia in the BESTCILIA trial.
26 Sep 2019
A recent study has suggested the use of spectrum analysis of endobronchial ultrasound (EBUS) radiofrequency in predicting malignant or benign peripheral pulmonary lesions (PPL) noninvasively in patients with lung cancer.
Audrey Abella, 2 days ago
Bronchial thermoplasty (BT) provided sustained improvements in patients with severe asthma, according to the results of the BT10+* study presented at ERS 2019.

Cardiac biomarkers pinpoint CAP patients at high risk of adverse CV events

20 Aug 2019

Cardiac biomarkers are useful for identifying community-acquired pneumonia (CAP) patients with an elevated risk of early and long-term cardiovascular (CV) events, according to a study.

Researchers followed 730 hospitalized CAP patients for 1 year. They measured several cardiovascular (proadrenomedullin [proADM], pro b-type natriuretic peptide [proBNP], proendothelin-1, and troponin T) and inflammatory biomarkers (interleukin 6 [IL-6], C-reactive protein [CRP] and procalcitonin [PCT]) at several time points (days 1, 4/5 and 30), exploring their utility for assessing early (within 30 days) or long-term (1 year follow-up) CV events.

A total of 92 patients developed an early CV event and 67 a long-term event. Patients who did vs did not develop CV events had markedly higher initial levels of proADM, proendothelin-1, troponin, proBNP and IL-6. Despite a drop at day 4/5, levels remained quite steady until day 30 in those who developed late events.

On multivariable regression analysis, several days 1 and 30 biomarkers independently predicted CV events, as follows: proendothelin-1 (odds ratio [OR], 2.25, 95 percent CI, 1.34–3.79), proADM (OR, 2.53, 1.53–4.20), proBNP (OR, 2.67, 1.59–4.49) and troponin T (OR, 2.70, 1.62–4.49) for early events, and proendothelin-1 (OR, 3.13, 1.41–7.80), proADM (OR, 2.29, 1.01–5.19) and proBNP (OR, 2.34, 1.01–5.56) for late events.

Furthermore, the addition of IL-6 levels at day 30 to proendothelin-1 or proADM strengthened these cardiac biomarkers’ association with late CV events (ORs, 3.53 and 2.80, respectively).

The findings highlight the usefulness of cardiac biomarkers, potentially aiding personalized treatment optimization and facilitating design of future interventional studies to reduce CV risk, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 14 Oct 2019
Use of the Zephyr endobronchial valve (EBV) led to significant improvements in a range of patient-reported outcomes (PROs) including multiple domains of respiratory symptoms and quality of life (QoL) in patients with severe emphysema, according to the post hoc results of the LIBERATE* trial presented at ERS 2019.
14 Oct 2019
Dr Helene Kobbernagel expounds on the role of azithromycin in primary ciliary dyskinesia in the BESTCILIA trial.
26 Sep 2019
A recent study has suggested the use of spectrum analysis of endobronchial ultrasound (EBUS) radiofrequency in predicting malignant or benign peripheral pulmonary lesions (PPL) noninvasively in patients with lung cancer.
Audrey Abella, 2 days ago
Bronchial thermoplasty (BT) provided sustained improvements in patients with severe asthma, according to the results of the BT10+* study presented at ERS 2019.